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Raman spectroscopic sensing of 
carbonate intercalation in breast 
microcalcifications at stereotactic 
biopsy
R. Sathyavathi1, 2, Anushree Saha1, Jaqueline S. Soares3, Nicolas Spegazzini4, 
Sasha McGee1, 5, Ramachandra Rao Dasari4, Maryann Fitzmaurice1 & Ishan Barman6, 7
Microcalcifications are an early mammographic sign of breast cancer and frequent target for 
stereotactic biopsy. Despite their indisputable value, microcalcifications, particularly of the type II 
variety that are comprised of calcium hydroxyapatite deposits, remain one of the least understood 
disease markers. Here we employed Raman spectroscopy to elucidate the relationship between 
pathogenicity of breast lesions in fresh biopsy cores and composition of type II microcalcifications. 
Using a chemometric model of chemical-morphological constituents, acquired Raman spectra 
were translated to characterize chemical makeup of the lesions. We find that increase in carbonate 
intercalation in the hydroxyapatite lattice can be reliably employed to differentiate benign from 
malignant lesions, with algorithms based only on carbonate and cytoplasmic protein content 
exhibiting excellent negative predictive value (93–98%). Our findings highlight the importance of 
calcium carbonate, an underrated constituent of microcalcifications, as a spectroscopic marker in 
breast pathology evaluation and pave the way for improved biopsy guidance.
Breast cancer is the most common malignant neoplasm and accounts for nearly a quarter of all cancers 
in women worldwide1. Spurred principally by mammography screening, an ever-increasing number of 
breast cancers are being detected before the development of axillary metastases2. However, while the 
increase in mammography screening has led to a dramatic increase in the detection of lesions, only 
10–25% of mammographically suspicious lesions are subsequently determined to be malignant3,4. This 
results in unnecessary and costly biopsy procedures.
One of the primary features of diagnostic importance in mammography is the appearance of micro-
calcifications, with up to 50% of all non-palpable breast cancers being linked with this marker5. Despite 
their obvious importance in the diagnostic and prognostic landscape, microcalcifications remain poorly 
understood and may often confound clinical decision making. Moreover, mammography does not pro-
vide the requisite information to classify the two types of microcalcifications observed in breast tissue that 
have vastly different implications in terms of the underlying lesion pathology6. Type I microcalcifications 
consist of pure crystalline calcium oxalate dihydrate (weddellite crystals) and are seen almost exclusively 
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in benign duct cysts and only rarely in non-invasive lobular carcinoma in situ7. These oxalate-type micro-
calcifications are most likely a product of sequestered duct secretions, and are therefore of little clinical 
concern. In contrast, type II microcalcifications are composed of calcium phosphates, mainly calcium 
hydroxyapatite with intercalated carbonate, deposited on a protein matrix and are associated with both 
benign and malignant proliferative lesions, including in situ and invasive ductal cancinoma8.
Owing to the clinical significance of microcalcifications, stereotactic breast needle biopsies are typi-
cally used to diagnose the mammographic lesion of interest. The complete diagnostic work up of such a 
process may require multiple interventional procedures leading to surging healthcare costs and a trau-
matic experience for the patient involved. Therefore, there is an urgent, unmet clinical need for a tool 
that can aid in targeted detection of type II microcalcifications and enable further differentiation between 
type II microcalcifications associated with benign lesions from those associated with malignancies. To 
address this need, our research has focused on the development of optical spectroscopy, especially Raman 
scattering, driven primarily by its exquisite molecular specificity and ability to perform real-time meas-
urements in a minimally invasive, non-destructive manner. Raman scattering is an inelastic scattering 
process in which photons incident on a sample transfer energy to or from the vibrational and rotational 
modes of molecules in the sample. It is a two-photon process and can be thought of as the simultaneous 
absorption of an incident photon and emission of a Raman photon. The difference between the ener-
gies of these two photons corresponds to the transition of a molecule from one energy level to another. 
Because the energy levels are unique for each molecule, Raman spectra of tissue consist of multiple 
bands characteristic of specific molecular motions and thus provide a chemical fingerprint of the breast 
tissue. As a result, Raman spectroscopy and its vibrational counterpart, i.e. Fourier Transform Infrared 
(FTIR) spectroscopy, have been extensively used to investigate breast malignancies9–12. Critically, Raman 
spectroscopy is particularly sensitive to symmetric vibrations such as the symmetric phosphate vibrations 
in hydroxyapatite in tissue mineralization such as breast microcalcifications. Previous studies by us and 
others have highlighted the potential of Raman spectroscopy to detect microcalcifications associated with 
benign and malignant breast lesions13–15.
In the efforts towards developing Raman spectroscopy as a clinical tool for real-time guidance of 
stereotactic breast biopsies, important clues can be drawn from initial investigations of isolated micro-
calcifications performed in formalin-fixed paraffin-embedded thin tissue sections13. Our prior study 
demonstrated the ability of Raman spectroscopy to distinguish type II microcalcifications associated with 
benign breast lesions from those associated with breast cancer. This was the first time that type II micro-
calcifications associated with benign and malignant breast lesions had been distinguished other than by 
histopathology diagnosis at breast biopsy. This later distinction was made using principle component 
analysis (PCA), a widely used dimension reduction and data exploration method, which requires no a 
priori information regarding the chemical composition of the tissue structures under study. Furthermore, 
inspection of the Raman spectra and PCA vectors suggested that the hydroxyapatite calcifications formed 
in benign ducts contain smaller amounts of protein and larger amounts of calcium carbonate than those 
formed in malignant ducts. A more recent FTIR-based investigation by Stone and co-workers supports 
this conclusion and has also shown that the carbonate content of hydroxyapatite microcalcifications 
decreases with increasing lesion grade16.
All these studies, nonetheless, have been confined to fixed tissue section analyses using microspectros-
copy, which represent an important first step but do not address the substantial complexity of real-time 
fiber probe-based measurements in tissue cores at stereotactic biopsy. While Raman spectroscopy can 
provide important structural information on the molecular composition of a cell or tissue sample, sam-
ple preparation can have a significant impact on the quantification and interpretation of spectra for 
their biochemical relevance. In particular, formalin fixing and paraffin embedding have been reported 
to affect a number of Raman features such as reduction of the amide-I peak (due to the formation of 
tertiary amides) and appearance of a new band at 1490 cm−1 17. Additionally, there is lack of consensus 
with regard to a standard protocol for deparaffinization of paraffin embedded sections for Raman inves-
tigations, as each of the deparaffinization processes (including the one employed in our earlier study) 
presents its own challenges. Critically, fiber-probe based measurements interrogate significantly larger 
sampling volumes as compared to the mentioned microspectroscopy systems and the diagnostic impact 
of this on the ability to differentiate lesion types based on type II microcalcification composition is yet 
to be determined.
The aim of this study is, therefore, to develop and validate decision algorithms derived from Raman 
spectra acquired from freshly excised breast tissue cores using fiber-probes that are compatible with 
standard 9-gauge biopsy needles. The overarching aim of the decision algorithms is to identify spectral 
markers that can be used to differentiate the nature of the underlying breast lesion associated with type 
II hydroxyapatite microcalcifications in vivo.
Results
Raman spectra were obtained from fresh breast biopsies from 26 patients undergoing stereotactic breast 
needle biopsy, using a compact Raman clinical system. Seventy-five of the tissue sites interrogated con-
tained breast lesions with type II microcalcifications. Since the principal goal of the study was to examine 
the relationship between the chemical composition of hydroxyapatite microcalcifications and the nature 
of the underlying breast lesion, all further analysis was restricted to these tissue sites harboring such 
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type II microcalcifications. Two were eliminated as outliers and provided poor model fits. The remaining 
73 Raman spectra constituting this data set could be divided according to the histological assessment 
in the following manner: 42 tissue sites from 15 patients were diagnosed as fibrocystic change (FCC); 
17 tissue sites from 6 patients diagnosed as fibroadenoma (FA); and 14 tissue sites from 5 patients 
diagnosed as invasive ductal carcinoma (IDC; n = 1) or ductal carcinoma in situ (DCIS; n = 13). FCC 
and fibroadenoma are among the most common benign conditions observed in the breast. FCC is an 
exaggerated response to hormonal changes during the menstrual cycle, manifested as fibrosis, adenosis 
or cyst formation18, whereas fibroadenoma is a benign tumor consisting of a fibroblastic stroma that 
contains elongated compressed ducts lined by benign appearing epithelium19.
Calcium carbonate contribution to the Raman spectra of breast lesions with type II microcal-
cifications. Figure  1a,b show typical Raman spectra of benign (FCC) and malignant (DCIS) breast 
lesions with type II microcalcifications, respectively, with the corresponding model fits and residuals. A 
prominent symmetric phosphate stretching mode band at 960 cm−1 is present in both of these Raman 
spectra, confirming the presence of type II hydroxyapatite microcalcifications. As detailed in our prior 
investigations on isolated microcalcifications, the Raman spectrum of pure stoichiometric calcium 
hydroxyapatite consists of four phosphate vibrational modes, two of which are outside the considered 
spectral range. The mentioned peak is attributed to the v1(PO4) mode of the “free” tetrahedral phosphate 
ion. However, in comparison to the sharp phosphate band at 960 cm−1 observed in the Raman spectrum 
of pure calcium hydroxyapatite (Fig.  1c), there is significant broadening of this feature in the spectra 
acquired from both benign and malignant breast lesions with type II microcalcifications.
Since broadening of this peak has been associated with the concomitant presence of calcium car-
bonate, further analyses were carried out to elucidate the impact of such carbonated apatite models 
on the diagnosis of breast lesions associated with microcalcifications. Broadening of the 960 cm−1 band 
was assessed quantitatively by measuring the full width at half maximum (FWHM) using an automated 
curve fitting algorithm that matches a Lorentzian profile with the experimental data. Table 1 shows the 
mean FWHM of the 960 cm−1 band (Fig.  1d) for the FCC, FA and DCIS/IDC groups. These results 
show a roughly 1.5-fold increase in the mean FWHM of the 960 cm−1 band for the benign breast lesion 
groups (FCC = 48.71; FA = 47.05) when compared with that for the malignant breast lesion group (DCIS/
IDC = 33.14). We believe that this broadening of the hydroxypatite phosphate band is due to intercalation 
Figure 1. Representative Raman spectra of (a) a benign breast lesion (FCC) and (b) a malignant breast 
lesion (DCIS) with type II microcalcifications, with model fits and residuals; (c) Raman spectra of 
pure calcium hydroxyapatite (CaHa) and calcium carbonate (CaCa); and (d) 960 cm−1 Raman feature, 
characteristic of apatite structures, acquired from a benign lesion with type II microcalcifications. The 
overlaid Lorentzian fit is used to compute the FWHM of the band and, thus, to provide a measure of the 
carbonate intercalation in the apatite structure.
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of carbonate ions into the apatite lattice, which reduces the symmetry of its unit cell20–21. The peak broad-
ening results from a loss of long-range translational order in the apatite structure, and increases as the 
carbonate content of the sample increases. It is worth noting that even though our custom-built fiber 
probe interrogates larger volumes consistent with the sampled tissue in standard 9-gauge biopsy needles, 
it has sufficient sensitivity to report on the differences between the lesions based on the carbonate inter-
calation, an underrated marker for breast pathology.
The presence of calcium carbonate is further evidenced by the presence of a smaller band at ca. 
1072 cm−1 in the Raman spectra of benign and malignant breast lesions with type II microcalcifications 
(Fig. 1a,b), which can be attributed to calcium carbonate v1(CO3) mode. The amount of calcium carbonate 
present was assessed quantitatively by determining the relative concentration of 9 Raman-active constit-
uents of breast tissue (calcium carbonate, calcium hydroxyapatite, calcium oxalate, epithelial cell nuclei 
and cytoplasm, stromal collagen fibers, fat cells, cholesterol-like extracellular deposits and beta-carotene) 
based on ordinary least squares modelling. Using this model, significant Raman fit coefficients (FC) for 
calcium hydroxyapatite, calcium carbonate and/or calcium oxalate were observed in all breast lesions 
harboring microcalcifications. The mean and standard deviation for the calcium carbonate fit coeffi-
cient (FC) for the FA, FCC and DCIS/IDC groups is provided in Table  1. These results again show a 
substantive increase in the mean calcium carbonate FC for the benign breast lesion groups (FCC = 5.13; 
FA = 3.60) when compared with that for the malignant breast lesion group (DCIS/IDC = 2.74) Employing 
both the FWHM of the 960 cm−1 peak and the calcium carbonate FC, statistically significant differences 
were observed between the benign and malignant groups (p < 0.05). The significance values were cal-
culated based on the Wilcoxon rank-sum test, which does not assume a normal distribution of data. 
Expectedly, a positive correlation between broadening of the 960 cm−1 phosphate band (FWHM) and 
the calcium carbonate content (FC) of the tissue site was also noted (r = 0.68). The slight discrepancy 
in the trends of computed FWHM and calcium carbonate FC values can be attributed to the different 
modeling approaches, namely Lorentzian fitting of the 960 cm−1 peak and ordinary least squares fitting 
of the spectral profile, and the inherent sources of error in each case. Due to the presence of only one 
IDC sample in the fresh tissue core dataset, it was not possible to determine the possibility of using cal-
cification parameters to differentiate between invasive and in situ carcinomas; but findings from Baker et 
al. point toward the presence of a progressive decrease in carbonate content from benign to increasingly 
malignant breast lesions13.
Table  2 shows the mean values and the standard deviations of the calcium carbonate to calcium 
phosphate FC ratios for the DCIS/IDC, FA and FCC groups. Here again the variations between the FCC 
and DCIS/IDC groups are evident with a nearly 2-fold increase in the calcium carbonate intercalation in 
the apatite structures for the former benign lesions. However, for the fibroadenoma tumors the ratios of 
carbonate to phosphate appear to be in the same range as that of the malignant group. Thus, this param-
eter proved to be less useful than the FWHM of the 960 cm−1 feature and the FC of calcium carbonate in 
parameter-based decision algorithms developed for the diagnosis of breast, described below.
Taken together, these results confirm our earlier inference that broadening of the 960 cm−1 phos-
phate band in the Raman spectra of isolated type II microcalcifications is due to intercalated calcium 
carbonate13, and show that this significant spectral finding can still be detected in the Raman spectra of 
tissue cores from breast lesions containing type II microcalcifications.
Lesion with 
Microcalcifications
FWHM 
960 cm−1(Mean ± SD)
Calcium 
Carbonate FC 
(Mean ± SD)
DCIS/IDC 33.14 ± 9.34 2.74 ± 3.71
FA 47.05 ± 8.78 (p = 0.0065) 3.60 ± 3.88 (p = 0.0001)
FCC 48.71 ± 6.90 (p = 0.015) 5.13 ± 4.98 (p = 0.0025)
Table 1.  Mean values of the FWHM of 960 cm−1 peak and the calcium carbonate FC in benign and 
malignant breast lesions with microcalcifications.
Lesion with Microcalcifications CaCa / CaHa Ratio
 DCIS/IDC 0.34 ± 0.57
 FA 0.35 ± 0.46
 FCC 0.76 ± 1.04 
Table 2.  Ratio of calcium carbonate to calcium phosphate FC in benign and malignant breast lesions with 
microcalcifications.
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Protein contribution to the Raman spectra of breast lesions with type II microcalcifica-
tions. The two major proteins present in breast tissue are actin, the predominant protein in the cyto-
plasm of ductal and lobular epithelial cells22, and collagen, the predominant protein in the extracellular 
stroma23, which is also present in the matrix of type II microcalcifications23. The contributions of these 
proteins to the Raman spectra of benign and malignant lesions with type II microcalcifications is not as 
easily seen on visual inspection as those of calcium hydroxyapatite and carbonate. However, the amount 
of these proteins present was assessed quantitatively by modeling of the Raman spectra. Table 3 shows 
the mean collagen and epithelial cell cytoplasm (actin) FC for the FA, FCC and DCIS/IDC groups. 
These results show a roughly 1.5-fold increase in the mean collagen FC for the benign breast lesion 
groups (FCC = 31.11; FA = 26.20) when compared with that for the malignant breast lesion group (DCIS/
IDC = 18.57). This is a similar trend to that seen with the calcium hydroxyapatite FWHM and calcium 
carbonate FC.
Our prior observations13 and those by other investigators16 in microspectroscopy studies of isolated 
type II microcalcifications showed an increase in protein, presumed to be matrix collagen, in type II 
microcalcifications associated with malignant breast lesions. The current result for the collagen FC in 
fresh breast biopsy tissue cores is, however, not surprising. This is because most collagen in benign or 
malignant breast lesions is present in the stroma and not in the microcalcifications, which again repre-
sent only a small fraction of the tissue. In contrast, we did observe a roughly 3- to 6-fold increase in the 
FC of epithelial cell cytoplasm (actin) in malignant lesions (DCIS/IDC = 12.36) when compared to that 
in benign breast lesions (FCC = 4.67; FA = 1.86) with type II microcalcifications, shown in Table 2. This 
is not surprising either, as DCIS and IDC are both proliferative lesions with increases in both the size 
and population density of malignant ductal epithelial cells23. Therefore ductal epithelial cells represent a 
larger fraction of the tissue in these malignant breast lesions than in benign breast lesions. To the best 
of our knowledge, this is the first spectroscopic study that links the presence of microcalcifications with 
the protein concentration of the ductal epithelial cells.
Calcium carbonate and protein-based empirical decision algorithms. In order to exploit 
the differences seen in calcium carbonate and cytoplasmic protein (actin)22, we sought to develop 
parameter-based decision algorithms to distinguish malignant from benign lesions with type II micro-
calcifications. To do this, we first assessed the likely diagnostic value of Raman spectral measurements of 
all 9 breast tissue model components using box plots. Box plots graphically depict groups of numerical 
data through their quartiles and help display differences between populations or samples without making 
any assumptions of the underlying statistical distribution. Here, the lower limit and upper limit of the 
box represent the first and third quartiles, and the center line represents the second quartile (median). 
From the box plots shown in Fig. 2, the benign (FCC/FA) and malignant breast lesions (DCIS/IDC) with 
type II microcalcifications show sufficient differentiation based on both the FWHM value of the 960 cm−1 
band and the FC of epithelial cell cytoplasm. The groups show reasonable separation based on the cal-
cium carbonate FC as well, though the overlap appears to be slightly greater than in the other cases. 
Indeed, the calcium carbonate FC and the FWHM value of the 960 cm−1 peak both provide quantitative 
measures of the carbonate intercalation in the apatite structures. Nevertheless, in this particular dataset, 
the FWHM value appears to provide better discrimination, which could likely be a result of the different 
modelling approaches used to arrive at these two measures.
Based on the results of the box plot analysis, we developed several diagnostic algorithms. In develop-
ing these algorithms, we considered the positive class to be cancer and the other classes, fibroadenoma 
and fibrocystic change, to be negative. The performance of the algorithms was assessed using the follow-
ing metrics: sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value 
(NPV) and overall accuracy (OA), based on the true positive (TP), false positive (FP), true negative (TN) 
and false negative (FN) results, per the standard definitions given below: SE = TP/(TP + FN); SP = TN/
(TN + FP); PPV = TP/(TP + FP); and NPV = TN/(TN + FN). We first devised two single-parameter Raman 
spectral algorithms to distinguish benign and malignant lesions with type II microcalcifications, one 
based on the FWHM of the 960 cm−1 band and the other on the FC of epithelial cell cytoplasm. The 
optimal threshold values for the single parameter decision algorithms were set empirically to maximize 
Lesion with 
Microcalcifications
Collagen FC 
(Mean ± SD)
Epithelial Cell 
Cytoplasm FC 
(Mean ± SD )
 DCIS/IDC 18.80 ± 13.19 12.12 ± 11.13
 FA 25.88 ± 12.97 (p = 0.002) 
1.39 ± 3.79 
(p = 0.01)
 FCC 31.03 ± 17.97 (p = 0.004) 
6.44 ± 8.14 
(p = 0.007)
Table 3. Mean values of collagen and epithelial cell cytoplasm FC in benign and malignant breast lesions 
with microcalcifications.
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the number of correct diagnoses of malignant breast lesions. Using an optimal decision threshold of 46, 
the 960 cm−1 band FWHM algorithm yielded a negative predictive value (NPV) of 98%, with a sensitivity 
(SE) of 93%, specificity (SP) of 75%, positive predictive value (PPV) of 46% and overall accuracy of 77%, 
for the distinction of malignant breast lesions (DCIS + IDC) from benign lesions (FCC + FA) with type 
II microcalcifications. In comparison, using an optimal threshold of FC = 9, the epithelial cell cytoplasm 
algorithm yielded a slightly decreased NPV of 93% and SE of 71%, but a slightly increased SP of 82%, 
PPV of 48% and overall accuracy of 80%.
Figure 2. Box plots summarizing the Raman spectra-derived data for the different breast lesions with type 
II microcalcifications: (a) the FWHM of the 960 cm−1 band, (b) the FC of calcium carbonate (CaCa) and (c) 
the FC of cytoplasmic protein content.
www.nature.com/scientificreports/
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To further improve diagnostic performance, we devised a 2-parameter decision algorithm using both 
the FWHM of the 960 cm−1 band and the FC of epithelial cell cytoplasm, shown in Fig. 3. Using a logistic 
regression-derived algorithm that optimizes the number of correct diagnoses of malignant breast lesions, 
the decision model yielded the same NPV as the single parameter epithelial cell cytoplasm algorithm 
(93%), but a further increase in SP to 85%, PPV to 53% and overall accuracy to 83%, for the distinction 
of malignant breast lesions (DCIS + IDC) from benign lesions (FCC + FA) with type II microcalcifica-
tions. The NPV of the empirical decision algorithms using fresh tissue measurements from breast lesions 
with type II microcalcifications is comparable to that achieved in our study of isolated type II microcalci-
fications using PCA (97%)13. Table 4 shows a side-by-side comparison of the performance of the decision 
algorithms developed in this study.
Discussion
Raman spectroscopy is well suited to the study of breast lesions with microcalcifications, as it provides a 
definitive chemical analysis of the lesional tissue and any microcalcifications it contains13,24–31. It has been 
used successfully to study other tissues with hydroxyapatite-based mineralization such as bone32,33. The 
bone studies have shown that the symmetric phosphate vibrations in hydroxyapatite in tissue minerali-
zation are sensitive to both the tissue microenvironment and ionic (in this case carbonate) intercalation 
into the hydroxyapatite matrix13. In particular, if the apatite lattice is disordered and/or amorphous, the 
phosphate symmetric stretch band is typically seen at 945–950 cm−1. If the apatite lattice is carbonate 
substituted, the phosphate symmetric stretch band is typically seen at 955–960 cm−1. For non-substituted 
crystalline apatite, the phosphate symmetric stretch band is typically seen at 962–964 cm−1. Further, for 
apatites with a carbonate substituted lattice, the phosphate symmetric stretch band around 960 cm−1 is 
broadened as also evidenced from our findings here14–16,34.
Breast microcalcifications are inherently complex materials that may be composed of various amounts 
of all three apatite species. However, the predominant apatite species in type II microcalcifications is the 
carbonate substituted apatite structures, as the dominant phosphate symmetric stretch band in breast 
Figure 3. Two-parameter Raman decision algorithm developed to distinguish malignant from benign breast 
lesions with type II microcalcifications. DCIS/IDC sites are depicted by red squares, while the FCC and FA 
lesions are marked by blue stars and blue circles, respectively.
Empirical Decision 
Algorithm SE SP PPV NPV OA
FWHM of 960 cm−1 
peak alone (threshold 
value = 46) 
93% 75% 46% 98% 77%
FC of cytoplasm 
protein alone 
(threshold value = 9) 
71% 82% 48% 93% 80%
FWHM of 960 cm−1 
peak vs. FC of 
cytoplasm protein 
71% 85% 53% 93% 83%
Table 4.  Comparison of performance of the empirical decision algorithms to distinguish benign from 
malignant breast lesions with type II microcalcifications.
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lesions in type II microcalcifications was seen at ~960 cm−1 in this study of fresh breast biopsy tissue cores 
and our previous study of formalin-fixed breast tissue sections13. At this time, the specific mechanism 
for hydroxyapatite formation and, more importantly, its role in breast tumor progression is not fully 
understood, although it is likely that the latter stems from several interconnected effects including direct 
enhancement of mitogenesis of mammary cells, upregulation of matrix metalloproteinases (MMPs) and 
increased expression of prostaglandin and inflammatory cytokines35.
In this study, we also observed a roughly 1.5-fold increase in calcium carbonate, as measured by 
the calcium carbonate model FC, in benign breast lesions (FCC/FA) as compared to malignant breast 
lesions (DCIS/IDC). Thus, in this study, we confirmed by quantitative measurements in fresh breast 
biopsy tissue cores what we had only inferred from our previous observations in isolated microcalcifica-
tions in fixed tissue sections. Furthermore, the presence of greater carbonate content in relatively benign 
lesions reinforces the idea that purely apatite structures are deposited by tumourigenic cells thereby indi-
cating specific mineralization potential may be associated with cell phenotype36. This shows that these 
carbonate-intercalation based spectral findings (first observed in isolated microcalcifications) can still 
be detected in the Raman spectra of breast lesions containing type II microcalcifications, even though 
microcalcifications represent only a small fraction of the tissue volume interrogated (Fig. 4).
In this study, we also observed an increase in collagen, as measured by the collagen FC, in benign 
breast lesions when compared with malignant breast lesions, which reflects stromal proliferation in 
benign breast lesions. We also observed for the first time an increase in actin, measured as the FC of 
epithelial cell cytoplasm, in malignant breast lesions when compared to that in benign breast lesions with 
type II microcalcifications. This observation is along expected lines as ductal epithelial cells represent a 
larger fraction of the tissue in malignant than in benign breast lesions.
Based on these results, we developed Raman decision algorithms to distinguish benign and malignant 
breast lesions with type II microcalcifications based on their calcium carbonate and protein (actin) con-
tent24. We observed that the overall performance was best for a 2-parameter empirical algorithm, which 
had a NPV of 95% and PPV of 61%. However, the best NPV (98%) was achieved, at the expense of a 
slightly worse PPV (46%), using a single parameter empirical algorithm based only on the FWHM of 
the 960 cm−1 feature. This single parameter algorithm has the potential advantage that it does not require 
spectral modelling (either employing PCA or our breast model), so data analysis could be faster making 
it easier to implement clinically than a model-based algorithm.
Conclusion and future directions. This pilot study represents the first demonstration of differen-
tiation of benign and malignant breast lesions using the carbonate intercalation signature in type II 
Figure 4. Photomicrograph of an H&E-stained breast biopsy tissue core harboring type II 
microcalcifications within a benign breast lesion (fibrocystic change)(4X). The box highlights the lesion 
interrogation volume. The microcalcifications (arrows) occupy only a small fraction of the overall tissue 
volume sampled by the Raman spectroscopy fiber-probe.
www.nature.com/scientificreports/
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microcalcifications in freshly excised tissue. Specifically, we show that the high specificity of the acquired 
Raman spectra allows differentiation between the underlying lesions harboring the microcalcifications 
with NPV of 93–98%. The data recorded in the present study also exhibits good agreement with our 
previous findings in formalin-fixed, deparaffinized thin tissue sections thereby confirming that that cal-
cium carbonate, a poorly understood and relatively unexplored constituent of breast microcalcifications, 
forms an important molecular marker – clinical translation of which can assist in defining cancer onset/
risk. Studies with a larger patient pool are currently under way at Johns Hopkins Medical Institutions 
to further expand and validate our diagnostic algorithm in this and other clinical settings. The precise 
merits of each parameter proposed here (FWHM of the 960 cm−1 peak, FC of calcium carbonate and car-
bonate to phosphate ratio) will also be re-evaluated through a prospective prediction on a larger cohort 
of patients. In particular, we would like to ascertain in vivo the linkage between chemical composition of 
microcalcifications and pathology grade/sub-grade of the associated lesions, as progression to invasion 
is commonly related to tumor grade. Ultimately, we envision that the microcalcification information can 
be coupled to recognized breast cancer markers, prominently the dynamic epithelial-stromal molecular 
“interactome”, to provide a comprehensive index for clinical diagnosis and prognostication.
Based on the promising results of this pilot study, we envision that this method can be readily trans-
lated to serve as a real-time guidance mechanism for stereotactic breast biopsies, improving microcalci-
fication retrieval and, as a result, enhancing the diagnostic yield. The upshot of such an approach would 
be to significantly reduce the excision of tissue cores that do not harbor clinically relevant lesions, despite 
harboring microcalcifications. Additionally, recent investigations suggest that microcalcifications may 
also predict more aggressive tumor behavior and poorer clinical outcomes37–39. The value-added infor-
mation provided by Raman spectroscopy could, therefore, also inform triaging of the small (~1–2 mm 
diameter) tissue cores for ancillary studies, routinely performed on breast cancer specimens to determine 
patient treatment strategy.
Methods
Patient population. Breast tissue was obtained from 26 patients (all female; ages 38–79) undergo-
ing vacuum assisted stereotactic core needle breast biopsy procedures in the Breast Health Center at 
University Hospitals-Case Medical Center. All studies were approved by the Case Cancer Institutional 
Review Board and the Massachusetts Institute of Technology Committee on the Use of Humans as 
Experimental Subjects. Informed consent was obtained from all subjects prior to their biopsy procedures. 
All experiments were performed in accordance with the approved guidelines and regulations.
Raman spectroscopy system. The portable clinical Raman spectroscopy system (instrument and 
optical fiber-probe based in these studies was developed at the Laser Biomedical Research Center at the 
Massachusetts Institute of Technology (MIT), previously described in detail40. The instrument uses an 
830 nm InGaAs diode laser (Process Instruments, Salt Lake City, UT) as an excitation source to deliver 
light to the tissue via a custom-designed optical fiber probe. The probe consists of a single excitation 
fiber surrounded by nine collection fibers. The excitation fiber terminates in a short-pass filter centered at 
830 nm that transmits the laser excitation light while blocking the fiber background (i.e. the Raman and 
fluorescence signal generated by the excitation fiber). The distal end of the probe has a sapphire ball lens 
that focuses the excitation light onto the tissue and collects the scattered light from the tissue into the 
nine collection fibers. The light on the collection path traverses through a long pass filter that suppresses 
the elastically scattered light emanating from the tissue to avoid further generation of a probe back-
ground. The linear array of collection fibers at the proximal end of the fiber is coupled to a spectrograph 
for dispersion onto a back illuminated, deep depletion, thermoelectrically-cooled CCD detector (PIXIS 
256, 26 × 26 μm pixels, 1024 × 256 array, Princeton Instruments). The laser power at the sample (freshly 
excised tissue cores) was maintained in the range of 98 to 105 mW. The Raman spectra were acquired 
by vertical binning prior to averaging 10 successive frames, each with an acquisition time of 0.25 s, for a 
total collection time of 2.5 s. The estimated tissue interrogation volume using our fiber-probe is 1.23 mm3 
driven by the functional requirement of detecting the presence of lesions in tissue cores with ca. 2 mm 
diameter41. While desirable for real-time biopsy guidance, the substantially larger interrogation volume 
may give rise to detection sensitivity issues, not observed in previous studies employing microspectros-
copy systems. Understanding and characterizing this trade-off is one of the focal points of the current 
investigation.
Data collection. All data were obtained ex vivo from freshly excised biopsy specimens in the Breast 
Health Center within 30 minutes of excision. The tissue cores collected during the needle biopsy proce-
dure were placed inside a Petri dish moistened with saline solution. Individual tissue cores of interest 
were then selected and placed sequentially on an aluminum block, which was in turn positioned inside 
a light-tight black box for data collection. Spectra were collected from several tissue sites of interest 
on each core (typically normal tissue, lesions (grossly abnormal tissue) without microcalcifications and 
lesions with microcalcifications) identified by gross inspection and in comparison with the specimen 
radiograph. Spectra were also collected from different cores in each biopsy and thus the number of 
spectra varied from patient to patient. Real time data analysis was used to help confirm data collection 
from tissue sites with microcalcifications.
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Following data collection, the tissue sites from which Raman spectra were obtained were marked with 
multicolored colloidal inks to uniquely identify each tissue site. The tissue was then fixed in 10% neutral 
buffered formalin, routinely processed, paraffin embedded, cut into tissue sections and stained with 
hematoxylin and eosin (H&E). The H&E stained tissue sections were then examined by an experienced 
breast pathologist, who was blinded to the results of the Raman analysis. The colored ink spots marking 
the sites interrogated spectroscopically were visible on the H&E stained tissue sections, and were used 
for comparison of histopathology and spectroscopy results. In our study, breast lesions were classified as 
harboring microcalcifications if microcalcifications were seen at that tissue site either on the specimen 
radiograph or on the H&E stained tissue sections.
Data analysis. The instrument was calibrated daily prior to data collection. Wave number calibra-
tion was performed using a spectrum from 4-acetamidophenol (Tylenol©) with known Raman peak 
positions. To correct the Raman spectra for the system wavelength response, a spectrum from a 
wavelength-calibrated tungsten halogen lamp diffusely scattered from a reflectance standard, barium 
sulphate (BaSO4), was used. Additionally, to eliminate the probe background, spectra were collected 
from a roughened aluminium surface. Different weightings of the aluminum spectra were subtracted 
with the optimal one chosen based on the tissue optical properties. Contributions from cosmic rays were 
removed using a derivative filter. Finally, to remove the background fluorescence, the spectra were least 
squares fitted with sixth order polynomials, which were then subtracted from the raw spectra before fur-
ther analysis. The data set was normalized to the most intense peak (1445 cm−1) to remove any possible 
intensity biases.
The calibrated, background subtracted and normalized Raman spectra were then fit with a previously 
developed breast model24, in which the Raman tissue spectrum is considered as a linear combination of 
its constituent basis spectra, Pi, and their concentrations, Ci, at wave number ω, equation (1).
S w C P w 1i i∑( ) = . ( ) ( )
In this study, the model includes basis spectra obtained from: epithelial cell nuclei, epithelial cell 
cytoplasm, fat cells, cholesterol-like extracellular deposits, beta-carotene, stromal collagen fibers, calcium 
oxalate (synthesized), reagent grade calcium hydroxyapatite (Sigma, St. Louis, MO, USA) and calcium 
carbonate (Sigma, St. Louis, MO, USA). The goal of the multivariate analysis was to predict the chemical 
composition of the interrogated tissue and in the process to determine chemical markers that could help 
indicate changes in function of the complex tissue matrix (i.e. presence of malignancy). Therefore, ordi-
nary least squares fitting was used to find the contribution of the spectra of the constituents of the basis 
model to each of the observed spectra by minimizing the sum of squared residuals, where the residual 
represents the difference between the acquired spectrum and the best fit value. This yields fit coefficients 
(FC) that are quantitative measures of the spectral contributions from the basis spectra thereby provid-
ing information about the morphological and biochemical composition of the tissue. The goodness of 
the fit was estimated qualitatively by visual inspection of the residual (measured spectrum minus model 
fit) and quantitatively by calculation of the standard deviation of the residual. In this regard, a Raman 
spectrum was eliminated from ensuing analysis if the standard deviation of the residual was observed 
to be greater than 0.2 or if it was determined to be an outlier using the Student’s t-test employing a 
Mahalanobis distance function.
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